Departmental homepageProfessor Abraham is Chief Investigator of multiple trials including the national PARTNER trial for high risk triple negative and hereditary breast cancer and the Personalised Breast Cancer Programme, which delivers real-time whole genome and whole transcriptome sequencing for clinical actionability. She is a member of the NIHR Clinical Studies Group for Breast Cancer, which sets the national clinical trials research strategy and she chairs the Genomics Working Group. She has also advised the National Institute for Health and Care Excellence on breast cancer therapeutics and has provided expert witness for the House of Commons Select Committee on Genomics and Gene Editing.
Professor Abraham directs the Biology of Disease course in Part IB, as well as giving supervisions and overseeing internal college examinations.
Her research focsues on developing innovative clinical trials in high risk and hereditary early-stage breast cancers, and using multi-modal data integration to develop predictive and prognostic tools to provide individualised treatment strategies for breast cancer patients to improve clinical outcomes.
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer. Abraham JE, Pinilla K, Dayimu A, et al. Nature, 2024 May; 629(8014):1142-1148. Epub 2024 Apr 8.
The Lancet Breast Cancer Commission. Coles CE, Earl H, Anderson BO, et al. Lancet Breast Cancer Commission. Lancet, 2024 May 11;403(10439):1895-1950. Epub 2024 Apr 15.
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Yau C, Osdoit M, van der Noordaa M, et al. Lancet Oncol, 2022 Jan;23(1):149-160. Epub 2021 Dec 11.
ctDNA monitoring using patient-specific sequencing and integration of variant reads. Wan JCM, Heider K, Gale D, et al. Sci Transl Med, 2020 Jun 17;12(548):eaaz8084.
